Takeda and Lundbeck lay out Phase III plans under depression alliance
This article was originally published in Scrip
Executive Summary
Takeda and Lundbeck have unveiled details of new pivotal Phase III programmes for two novel molecules for major depressive disorder (MDD) being co-developed under their 2007 alliance for mood and anxiety disorder drugs.